All News

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

My survivor friends and I share the insensitive comments we have received about our cancer diagnosis.

Bone pain is a common symptom that patients with multiple myeloma face, but some may find relief with treatments and exercise.

Patients with stage 3 melanoma, a type of skin cancer, that has metastasized to the lymph nodes may benefit from skipping lymph node removal surgery and receiving treatment with adjuvant therapy, although more research is needed in this area.

The use of bempegaldesleukin and Opdivo failed to meet its goal of significantly improving progression-free survival and responses to treatment, compared with Opdivo alone in patients with previously untreated unresectable or metastatic melanoma, according to data from an initial analysis of the phase 3 PIVOT IO-001 study.

Although certain cancer treatments have been linked to an increased risk of a secondary cancer years later, an expert notes there are no genetic or pathologic studies that prove the association between new and previous cancers.

My father was an alcoholic, and though he died in 1992, he lives on through my siblings and me because we all inherited a cancer syndrome from him.

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Cindy Cherry, MSN, AGNP-C, and cancer patient Dorothy T. share their experiences with cancer and how they approach chemotherapy treatment.

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.

One of the hurdles, according to the study’s lead author, is that many patients with cancer are worried about receiving a placebo in a clinical trial.

Eventually, my daughter will stop seeing her oncologist, and while I appreciate all that he has done, I hope that they part ways forever.

In honor of CURE®’s 20th anniversary, we spoke with experts on how the past 20 years have revolutionized multiple myeloma treatment.

During my treatment for triple-negative breast cancer, there was a plan for every situation, but once I entered survivorship, I was in uncharted territory.

Many things can influence a patient’s response to the COVID-19 vaccine, such as their treatments or whether they have a higher tumor burden.

I’d become an eating machine with a loathsome attitude on prednisone, so I decided to conduct my own taper of the drug.

It can be difficult for patients to go about their daily life with this bone pain, so what can help?

The FDA’s decision to greenlight Opdualag is based on data that showed that the combination more than doubled survival without disease progression when compared with Opdivo in patients with previously untreated metastatic or unresectable melanoma, a type of skin cancer.

Approximately 100,000 patients with stage 1 to stage 3 solid tumors will be enrolled onto the trial across 25 sites, according to the manufacturer of the test aimed at detecting cancer recurrence.

As part of its “Speaking Out” video series, CURE® spoke with Throwing Bones founder Kenny Capps about the importance of patient-physician communication during a myeloma journey.

There’s a fine line between toxic positivity and encouragement. Myself and other cancer survivors know that all too well.

From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.

Donna McNutt uses her love of fashion to find confidence and motivation — and shares it with others — after a myeloma diagnosis.

The early-stage trial, according to the investigational drug’s manufacturer, Adagene, is expected to take place across multiple sites in the United States and Asia Pacific.

When cancer harms the body’s ability to make antibodies, what does that mean for the efficacy of vaccines?

The season of spring represents new awakenings for me, and this year, I’m determined to bring an air of positivity to my life and my cancer experience.

One patient with stage 4 kidney cancer pivoted from being a journalist to a patient advocate, educating patients and others about a cancer that requires more awareness and research funding.

Durable and deep responses occurred in patients with multiple myeloma after use of a particular CAR-T cell therapy

Four sites across the United States are enrolling patients with locally advanced or metastatic pancreatic cancer to see if a novel drug combined with standard-of-care chemotherapy bests chemotherapy alone in survival outcomes and responses to treatment.